Medicinal Chemistry, Cardiovascular & Gastrointestinal Innovative Medicines Unit, AstraZeneca R&D, Pepparedsleden 1, SE-431 83 Mölndal, Sweden.
Expert Opin Ther Pat. 2012 Dec;22(12):1467-77. doi: 10.1517/13543776.2012.743994. Epub 2012 Nov 8.
AMP-activated protein kinase (AMPK), a heterotrimeric protein complex with serine/threonine kinase activity has a central role in controlling cellular energy expenditure. Small molecule-based activation of AMPK represents an attractive therapeutic proposition because of AMPK's ability to regulate several anabolic and catabolic pathways that are critical to the development of metabolic disorders and cancer.
A comprehensive review of published patents that disclose direct AMPK activators is provided: 26 patents comprising 10 chemical classes, and supporting in vitro and in vivo data are discussed.
AMPK activation holds promise as a possible pharmacological intervention in several disease states. The development of direct, highly specific AMPK activators is necessary to fully realize the opportunities linked to AMPK activation and appreciate the risks associated with it.
AMP 激活的蛋白激酶(AMPK)是一种具有丝氨酸/苏氨酸激酶活性的异三聚体蛋白复合物,在控制细胞能量消耗方面起着核心作用。基于小分子的 AMPK 激活因其能够调节几种对代谢紊乱和癌症的发展至关重要的合成代谢和分解代谢途径而成为一种有吸引力的治疗方案。
提供了对公开专利的全面审查,这些专利揭示了直接的 AMPK 激活剂:26 项专利包括 10 个化学类别,并讨论了支持体外和体内数据。
AMPK 的激活有望成为几种疾病状态的一种潜在的药理学干预手段。需要开发直接的、高度特异的 AMPK 激活剂,以充分实现与 AMPK 激活相关的机会,并认识到与之相关的风险。